Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Amyotrophic Lateral Sclerosis (ALS)
- Main trialPhase 3
- “The purpose of this study is to assess the long-term safety and tolerability of tirasemtiv in patients with ALS who had completed the double-blind placebo-controlled study of tirasemtiv in ALS (CY 4031).”In the company’s words, NCT02936635 on ClinicalTrials.gov
- Other names
- CK-2017357
Other drugs for Amyotrophic Lateral Sclerosis (ALS)
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 26 Oct 2018 | A Study for Patients Who Completed VITALITY-ALS (CY 4031) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026